Abstract
Background
The MDR1 gene presents several genetic polymorphisms with pharmacological implications. Therefore, the aim of the present study is to establish the genotype and allele frequencies of 3435C>T polymorphism of MDR1 gene into Peruvian populations (Coastal, Andean and Amazonian ecoregions), even considering the altitude (lowland <2500 m and highland >2500 m).
Methods
The polymorphism was analyzed by TaqMan genotyping assays in a group of 181 healthy unrelated Peruvian individuals. The comparison of genotype and allele frequencies of 3435C>T polymorphism was made with the Pearson test (X2), and, to calculate the genotype distributions, the Hardy-Weinberg equilibrium (HWE) was used.
Results
In all populations evaluated in this study, the genotype frequency distributions met HWE assumptions. The comparison between genotype and allele frequencies showed significant differences (p < 0.05), when the Andean, Coastal and Amazonian populations were compared. Also, significant differences (p < 0.05) were obtained when these populations were compared considering their altitudes. Likewise, in comparison with countries like USA, Finland, Nigeria and Kenya, the results showed significant differences (p < 0.05).
Conclusions
This investigation allowed us to establish the genotype and allele frequencies of 3435C>T polymorphism in different Peruvian populations, considering the geographic localization and even the altitude.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Universidad de San Martin de Porres - Facultad de Medicina Humana and Universidade de São Paulo - Faculdade de Medicina de Ribeirão Preto
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
[1] Dean M, Rzhetsky A, Allikmets R. The human ATP-Binding Cassette (ABC) transporter superfamily genome. Genome Res 2001;11:1156–66.10.1101/gr.184901Search in Google Scholar
[2] Ng WF, Sarangi F, Zastawny RL, Venot-Drebot L, Ling V. Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 1989;9:1224–32.Search in Google Scholar
[3] Cordon-Cardo C, O’brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277–87.10.1177/38.9.1974900Search in Google Scholar
[4] Borst P, Schinkel AH, Smit JJM, Wagenaar EVDL, Van Deemter L, Smith AJ, et al. Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 1993;60:289–99.10.1016/0163-7258(93)90011-2Search in Google Scholar
[5] Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 2003;55:425–61.10.1124/pr.55.3.1Search in Google Scholar PubMed
[6] Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ. Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monitor 2004;10:5–14.Search in Google Scholar
[7] Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655–60.Search in Google Scholar
[8] Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004;27:257–64.10.1111/j.1365-2885.2004.00607.xSearch in Google Scholar PubMed
[9] Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998;91:1749–56.10.1182/blood.V91.5.1749Search in Google Scholar
[10] Ieiri I, Takane H, Otsubo K. The MDR1 (ABCB1) gene polymorphism and its clinical implications. Clin Pharmacokinet 2004;43:553–76.10.2165/00003088-200443090-00001Search in Google Scholar PubMed
[11] Ladislava B, Michal K, Katerina W, Milan B. Gene polymorphisms and inflammatory bowel disease. Inflamm Bowel Dis 2012;176:1093–6.10.5772/53465Search in Google Scholar
[12] Xie HG, Kim R, Wood A, Stein M. Molecular basis of ethnic differences in drug disposition and response. Ann Rev Pharmacol Toxicol 2001;41:815–50.10.1146/annurev.pharmtox.41.1.815Search in Google Scholar PubMed
[13] Frassetto L, Mancinelli L, Christians U. Fluconazole-induced changes in tacrolimus oral bioavailability in three ethnic groups. In Millennial World Congress of Pharmaceutical Sciences. 2000; 16–20.Search in Google Scholar
[14] Mancinelli LM, Frassetto L, Floren LC, Dressler D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24–31.10.1067/mcp.2001.113183Search in Google Scholar PubMed
[15] Hoffmeyer S, Burk O, Von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proceedings of the National Academy of Sciences. 2000;97:3473–8.10.1073/pnas.97.7.3473Search in Google Scholar PubMed PubMed Central
[16] Galanter JM, Fernandez-Lopez JC, Gignoux CR, Barnholtz-Sloan J, Fernandez-Rozadilla C, Via M, et al. Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas. PLoS genet 2012;8:e1002554.10.1371/journal.pgen.1002554Search in Google Scholar PubMed PubMed Central
[17] Wang S, Ray N, Rojas W, Parra MV, Bedoya G, Gallo C, et al. Geographic patterns of genome admixture in Latin American Mestizos. PLoS Genet 2008;4:e1000037.10.1371/journal.pgen.1000037Search in Google Scholar PubMed PubMed Central
[18] Lexus Edit. Gran Enciclopedia del Perú (Barcelona, España, 1998).Search in Google Scholar
[19] Cavalli-Sforza LL, Piazza A, Menozzi P, Mountain J. Reconstruction of human evolution; bringing together genetic, archaeological and linguistic data. Proc Natl Acad Sci USA 1988;85:6002–6.10.1073/pnas.85.16.6002Search in Google Scholar PubMed PubMed Central
[20] Sandoval JR, Salazar-Granara A, Acosta O, Castillo-Herrera W, Fujita R, Pena S, et al. Tracing the genomic ancestry of Peruvians reveals a major legacy of pre-Columbian ancestors. J Hum Genet 2013;1–8.10.1038/jhg.2013.73Search in Google Scholar PubMed
[21] Miura DS. Genetic factors in human hypertension. Curr Opin Nephrol Hypertens 1997;215–8.10.1097/00041552-199705000-00003Search in Google Scholar PubMed
[22] Cambien F, Poirier O, Nicaud V, Herrmann SM, Mallet C, Ricard S, et al. Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet 1999;65:183–91.10.1086/302448Search in Google Scholar PubMed PubMed Central
[23] Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemostasis 2001;85:584–95.10.1055/s-0037-1615638Search in Google Scholar
[24] Rupert JL, Hochachka PW. The evidence for hereditary factors contributing to high altitude adaptation in Andean natives: a review. High Alt Med Biol 1991;2:235–56.10.1089/152702901750265332Search in Google Scholar PubMed
[25] 1000 Genomes Project: Peruvians from Lima, Peru. http://grch37.ensembl.org/Homo_sapiens/Variation/Population?r=7:87138145-87139145;v=rs1045642;vdb=variation;vf=759497#373532_tablePanel.Search in Google Scholar
[26] Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 2004;5:645.10.1038/nrg1432Search in Google Scholar PubMed
[27] Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS, et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenet Genom 2002;12:437–50.10.1097/00008571-200208000-00004Search in Google Scholar
[28] Marsh S, King CR, Van Booven DJ, Revollo JY, Gilman RH, McLeod HL. Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 2015;16:441–8.10.2217/pgs.15.10Search in Google Scholar
[29] Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka H, Itoda M, Koyano S, et al. Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. Drug Metab Pharmacok 2004;19:83–95.10.2133/dmpk.19.83Search in Google Scholar
[30] Ruiz-Linares A, Adhikari K, Acuña-Alonzo V, Quinto-Sanchez M, Jaramillo C, Arias W, et al. Admixture in Latin America: geographic structure, phenotypic diversity and self-perception of ancestry based on 7,342 individuals. PLoS Genet 2014;10:e1004572.10.1371/journal.pgen.1004572Search in Google Scholar
[31] Elmore JG, Moceri VM, Carter D, Larson EB. Breast carcinoma tumor characteristics in black and white women. Cancer 1998;83:2509–15.10.1002/(SICI)1097-0142(19981215)83:12<2509::AID-CNCR15>3.0.CO;2-VSearch in Google Scholar
[32] Marchi N, Granata T, Alexopoulos A, Janigro D. The blood-brain barrier hypothesis in drug resistant epilepsy. Brain Res 2012;135:e211.10.1093/brain/awr343Search in Google Scholar
[33] Qosa H, Miller DS, Pasinelli P, Trotti D. Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders. Brain Res 2015;1628:298–316.10.1016/j.brainres.2015.07.005Search in Google Scholar
[34] Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248–60.10.1016/S0009-9236(97)90027-8Search in Google Scholar
[35] Göktaş MT, Pepedil F, Karaca Ö, Kalkışım S, Cevik L, Gumus E, et al. Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Eur Rev Med Pharmacol Sci 2016;20:2460–7.Search in Google Scholar
[36] Rupert JL, Kidd KK, Norman LE, Monsalve MV, Hochachka PW, Devine DV. Genetic polymorphisms in the renin-angiotensin system in high-altitude and low-altitude native American populations. Ann Hum Genet 2003;67:17–25.10.1046/j.1469-1809.2003.00004.xSearch in Google Scholar
[37] Moore LG. Human genetic adaptation to high altitude. High Alt Med Biol 2001;2:257–79.10.1089/152702901750265341Search in Google Scholar
[38] Katsuya T, Koike G, Horiuchi M, Pratt RE, Dzau VJ, Yee TW, et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1600–3.10.1016/S0140-6736(95)90115-9Search in Google Scholar
[39] Atwood LD, Kammerer CM, Samollow PB, Hixson JE, Shade RE, MacCluer JW. Linkage of essential hypertension to the angiotensinogen locus in Mexican Americans. Hypertension 1997;30:326–30.10.1161/01.HYP.30.3.326Search in Google Scholar
[40] Wang WYS, Zee RYL, Morris BJ. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 1997;51:31–4.10.1111/j.1399-0004.1997.tb02410.xSearch in Google Scholar
[41] Szombathy T, Szalai C, Katalin B, Palicz T, Romics L, Csaszar A. Association of angiotensin II type 1 receptor polymorphism with resistant essential hypertension. Clin Chim Acta 1998;269:91–100.10.1016/S0009-8981(97)00184-8Search in Google Scholar
[42] Jacovas VC, Rovaris DL, Peréz O, de Azevedo S, Macedo GS, Sandoval JR, et al. Genetic variations in the TP53 pathway in Native Americans strongly suggest adaptation to the high altitudes of the Andes. PLoS One 2015;10:e0137823.10.1371/journal.pone.0137823Search in Google Scholar PubMed PubMed Central
©2019 Walter de Gruyter GmbH, Berlin/Boston
